Dicot's nomination committee proposes Fredrik Buch and Michael Zell as new Board members
Press release: Uppsala, April 7, 2022. The Nomination Committee of Dicot AB proposes that Fredrik Buch and Michael Zell are elected as new ordinary Board members of the Board of Dicot AB at the Annual General Meeting on May 24.
The Nomination Committee consisting of Rune Löderup (Chairman) and Jarl Wikberg with Chairman of the Board Eva Sjökvist Saers as convener has decided to propose Fredrik Buch and Michael Zell to Dicot AB's Board. With these members, the current Board is supplemented with additional experience in business development, licensing and international partnerships, as well as with investor and shareholder perspectives. Michael Zell was previously a member of the Nomination Committee but was dismissed when he was proposed as a Board member.
Fredrik Buch is a Medical Doctor and Ph.D with a degree from the University of Gothenburg. Fredrik's professional activities include medical research and clinical activities, medical R&D in the pharmaceutical industry as well as fund management and venture capital/investments. Fredrik has been active in e.g. Sahlgrenska University Hospital in Gothenburg and the University Hospital in Uppsala. This was followed by a couple of years as Medical Director at Pharmacia/Pharmacia & Upjohn and Svenska Hoechst AB, Squibb AB/Bristol Myers Squibb AB Scandinavia. Fredrik has been Head of SEB Läkemedelsfonder, partner at HealthCap, partner and founder of Brilleon Capital and has been active as a venture consultant for Karolinska Investment Fund. Fredrik Buch has extensive experience from Board work and is currently active in the Boards of e.g. Lobsor Holding AB, Intrance Medical System Inc/Intrance Holding AB, Cytovac A/S, Pila B and Acarix AB.
Michael Zell has a master’s degree in Economics from the Stockholm School of Economics with an Executive Education from Harvard Business School. He began his professional career with a few years in the navy and at Rederi AB Nordstjernan. Since then, Michael has had a long career at Handelsbanken in several senior positions such as Vice President of the bank and CEO of a number of central subsidiaries. In that capacity, he was part of the bank's Group Management for more than 20 years, with responsibility for the bank's operations in Greater China as the last assignment before his retirement. Since then, Michael has been appointed chairman of the Swedish Ship Mortgage Fund by the government. During 2014-2018, he was president of the Royal Örlogsmannasällskapet - Swedish Marine Academy. Michael Zell has been a shareholder in Dicot AB since the company's listing in 2018 and has participated in all issues.
The Nomination Committee proposes re-election of Eva Sjökvist Saers, Mikael von Euler, Per-Göran Gillberg and Lena Söderström. The Nomination Committee proposes new election of Fredrik Buch and Michael Zell. The Nomination Committee proposes Eva Sjökvist Saers as Chairman of the Board.
Ebba Florin-Robertsson and Claes Post have declined re-election.
For further information, please contact:
Eva Sjökvist Saers, Chairman of the Board
Tel: +46 705 50 73 71
Email: Eva.Sjokvist.Saers@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.